Tag Archives: Reuters

Alarming Harvard study predicts over half of US children will be obese by age 35. Time to embrace the “Nanny State?”

The News: Nearly three in five children in the US today are destined to be obese when they reach their 35th birthday, according to a new projection that Reuters reports…. Read more »

Pfizer, Merck’s Bavencio flop illustrative of shattered Pharma model. Is industry’s collapse just around the corner?

The News: Pfizer Inc. (NYC) and its German part­ner Merck KGaA (Darmstadt) have run into a brick wall in their race to ex­pand the mar­ket for their PD-L1 check­point inhibitor Baven­cio… Read more »

Trump does end-run around Congress, scraps Obamacare insurer subsidies via executive order; what’s really happening?

The News: An alliance of US states joined ranks on Friday (October 13, 2017) to sue to block President Donald Trump’s move to dump a key component of Obamacare–subsidies to… Read more »

Innovio’s DNA-based Zika vaccine is safe and effective at inducing immune response; where has this breakthrough vaccine technique been hiding?

The News: A DNA-based Zika vaccine from Inovio Pharmaceuticals Inc. (Plymouth Meeting PA) and South Korea’s GeneOne Life Science Inc. induced anti-Zika immune responses in an early stage human trial,… Read more »

Alnylam soars on RNAi success as Phase 3 patisiran study hits all goals; market overreacts as pipeline unproven and competition lurks.

The News: Alnylam Pharmaceuticals Inc.’s (Cambridge MA) RNAi-based drug that targets a rare genetic disease cleared a key study, in a breakthrough for the new class of medicines that works… Read more »

Pfizer granted Prevnar patent from India; drugmaker draws quick fire for pricing, access.

The News: India has granted Pfizer Inc. (NYC) a patent for its powerful pneumonia vaccine Prevenar 13, in a blow to some health groups that said this would put the… Read more »

Endo coming out of the darkness into the light; contrarians, buy this name.

The News: Endo International Plc (Dublin IRL) on Tuesday (August 8, 2017) lowered its full-year revenue forecast, saying it expected lower sales of branded drugs to add to the pricing… Read more »

Biogen’s poster presentation for Alzheimer’s candidate hardly noticed at London AAIC meeting as market focuses on quarterly results instead; start accumulating.

Biogen Inc. (Cambridge MA) laid out long-term plans to strengthen its core multiple sclerosis (MS) business, develop more neuroscience drugs and shop for late-stage assets, after reporting robust second-quarter results,… Read more »

Rx Hall of Shame Update: Former Insys employee pleads guilty in US opioid drug probe; case against ex CEO Michael Babich, others, in pre-trial mode.

The News: A former employee of Insys Therapeutics Inc. (Chandler AZ) pleaded guilty last week to having conspired to defraud insurers into paying for an expensive fentanyl-based drug that is… Read more »

What’s wrong with Novartis? Actually nothing.

The News: Novartis AG (Basel CHE) has been the subject of widespread and lingering chatter to the effect that its stature among the Big Pharma league players has diminished, and… Read more »